Security key
13463J101
Camp4 Therapeutics Corp - Common Stock, par value $0.0001 per share (CAMP)
CUSIP: 13463J101
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 11,744,129
- Total 13F value
- $17,029,220
- Share change
- -933,574
- SEC-reported price per share
- $1.45
- Number of holders
- 28
- Value change
- -$3,217,598
- Number of buys
- 12
- Number of sells
- 28
- Shares outstanding
- 51,921,834
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
28
Top holders
10
CAMP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Camp4 Therapeutics Corp SEC filings
Camp4 Therapeutics Corp company facts
Broader feeds
Reporting periods
Holder history for CUSIP 13463J101
Recent filing periods:
Ownership snapshot
Top reported holders of CAMP - Camp4 Therapeutics Corp - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Enavate Sciences GP, LLC
Disclosed value leader
Enavate Sciences GP, LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
3/4/5
Lead comparable stake: 7.3%
Showing 1-6 of 15 holder rows.
Quick read
Enavate Sciences GP, LLC leads the comparable SEC ownership view at 7.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Enavate Sciences GP, LLC's linked filing trail.
Comparable ownership
Top 5
Enavate Sciences GP, LLC
7.3%
5AM Venture Management, LLC
5.6%
a16z Capital Management, L.L.C.
4.1%
HARBOURVEST PARTNERS LLC
2.4%
FMR LLC
1.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Enavate Sciences GP, LLC |
13F
3/4/5
Company · 10%+ Owner
|
7.3%
|
$15,143,208
3,785,802 shares
|
— | 31 Mar 2025 |
| 5AM Venture Management, LLC |
13F
Company
|
5.6%
|
$11,711,660
2,927,915 shares
|
— | 31 Mar 2025 |
| a16z Capital Management, L.L.C. |
13F
Company
|
4.1%
|
$8,501,356
2,125,339 shares
|
— | 31 Mar 2025 |
| HARBOURVEST PARTNERS LLC |
13F
Company
|
2.4%
|
$5,087,792
1,271,948 shares
|
— | 31 Mar 2025 |
| FMR LLC |
13F
Company
|
1.5%
|
$3,067,788
766,947 shares
|
— | 31 Mar 2025 |
| FRANKLIN RESOURCES INC |
13F
Company
|
1.2%
|
$2,540,216
635,054 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
28
Shares
11,744,129
Rows available
28
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
39
Q2 2025 holders
28
Holder diff
-11
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend